ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1828

CD14+CXCL10+Monocytes Remodel the Peripheral Immune Network in sJIA via UBE2D1-Driven Inflammatory Programming

Xuemei Tang1, Qiang Luo2, Jun Yang3, Haiguo Yu4, Xinglin Wu1, Xiwen Luo5, Xi Yang5, Zhiyong Zhang5, Yunfei An5, Xiaodong Zhao1 and Hongmei Song6, 1Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), 2Department of Rheumatology and Immunology, Children’s Hospital of Chongqing Medical University, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China (People's Republic), 3Rheumatology and Immunology Department of Shenzhen Children's Hospital, Shenzhen, 518100, China., Shenzhen, China (People's Republic), 4Department of Rheumatology and Immunology, Nanjing Children's Hospital, Nanjing, 210000, China., Nanjing, China (People's Republic), 5Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), 6Pediatric Department of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100000, China., Beijing, China (People's Republic)

Meeting: ACR Convergence 2025

Keywords: Juvenile idiopathic arthritis, Monocytes/macrophages, Mouse Models, Other

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1809–1829) Pediatric Rheumatology – Basic Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disorder characterized by systemic immune dysregulation. However, reliable biomarkers to predict its unpredictable disease course are still lacking. Identifying immune cell subsets and molecular drivers of disease progression is crucial for improving prognosis and developing targeted therapies.

Methods: We performed comprehensive immunophenotypic profiling of PBMCs from sJIA patients across five clinical centers. Deconvolution analysis combined with clinical follow-up in the Chongqing cohort was used to assess the prognostic value of key subpopulations. In vivo validation was performed using UBE2D1 knockout mice. A cross-disease single-cell reference was developed to compare sJIA-associated immune subsets with those found in other inflammatory diseases.

Results: We identified a novel CD14+CXCL10+monocyte subset distinguished by a unique transcriptomic signature enriched in immune regulatory genes. Notably, flow cytometry revealed that this subset was significantly elevated during the active phase of sJIA and decreased during remission, demonstrating a strong correlation with disease activity. In vitro inflammatory stimulation promoted the differentiation of monocytes into the CXCL10+phenotype. But, this process was markedly impaired in UBE2D1-deficient mice, which exhibited lower expression of CXCL10 mediators, underscoring the pivotal role of UBE2D1 as a central driver of this inflammatory program. Finally, by comparing this subset with other JIA subtypes and inflammation-related diseases, we found that it exhibits a distinct expression pattern in sJIA.

Conclusion: Our findings suggest that UBE2D1-driven CD14+CXCL10+monocyte play a key role in sJIA pathogenesis and may serve as both a biomarker and therapeutic target for disease monitoring and intervention.

Supporting image 1Figure 1: Exploration of CD14+CXCL10+Monocyte Function

(A)Exploration of Biological Functions of CD14+CXCL10+Monocyte. (B) Violin plot showing CD14+CXCL10+monocyte levels across pJIA, ERA, oJIA, controls, and sJIA. (C) ROC curve illustrating the diagnostic performance of CD14+CXCL10+monocyte for distinguishing sJIA. (D) Differential expression of monocyte subpopulations in sJIA patients with and without remission. (E) Dot plot showing the Spearman’s correlations of CD14+CXCL10+monocyte and clinical features across the Chongqing Clinical Dataset (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). (F) Flow cytometry analysis of CD14+CXCL10+monocyte in peripheral blood of sJIA patients and controls. Left: Representative flow cytometry plots showing the percentage of CD14+CXCL10+monocyte in PBMCs from sJIA patients (top row) and controls (bottom row). Top right: Quantification shows that the proportion between sJIA and controls. Bottom right: Longitudinal analysis in the progression of sJIA disease.

Supporting image 2Figure 2: Exploration of CD14+CXCL10+Monocyte Core Network

(A-B) Expression of CXCL10 gene and protein in THP-1 cells under different inflammatory stimuli in vitro. (C) Overlapping DEG genes between sJIA internal and external datasets. (D) DEG analysis in post-treatment sJIA and control. (E) Dot plot showing the Spearman’s correlations of UBE2D1 and feature genes (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). (F) Time-course plot showing arthritis scores over 15 days: UBE2D1⁺/⁻ CAIA mice and WT CAIA mice (****p < 0.0001). (G) Representative multiplex immunofluorescence staining images of joint tissues from four experimental groups: UBE2D1⁺/⁻ CON, UBE2D1⁺/⁻ CAIA, WT CON, and WT CAIA.

Supporting image 3Figure 3: CD14+CXCL10+ monocyte Show Disease-Specific in Kawasaki Disease, BLAU, sepsis, and sJIA

(A) CD14+CXCL10+ monocyte enriched in sepsis samples. (B) CD14+CXCL10+ monocyte enriched in Kawasaki Disease (KD samples. (C) CD14+CXCL10+ monocyte enriched in BLAU samples. (D) CD14+CXCL10+ monocyte enriched in BLAU samples. (E) Ratio of observed to expected proportions of CD14+CXCL10+ monocyte across four disease. (F) Violin plots displaying UBE2D1 expression levels in CD14+CXCL10+ monocyte from each disease cohort.


Disclosures: X. Tang: None; Q. Luo: None; J. Yang: Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties, 5; H. Yu: None; X. Wu: None; X. Luo: None; X. Yang: None; Z. Zhang: None; Y. An: None; X. Zhao: None; H. Song: None.

To cite this abstract in AMA style:

Tang X, Luo Q, Yang J, Yu H, Wu X, Luo X, Yang X, Zhang Z, An Y, Zhao X, Song H. CD14+CXCL10+Monocytes Remodel the Peripheral Immune Network in sJIA via UBE2D1-Driven Inflammatory Programming [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/cd14cxcl10monocytes-remodel-the-peripheral-immune-network-in-sjia-via-ube2d1-driven-inflammatory-programming/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd14cxcl10monocytes-remodel-the-peripheral-immune-network-in-sjia-via-ube2d1-driven-inflammatory-programming/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology